SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001129928-23-000067
Filing Date
2023-11-03
Accepted
2023-11-03 11:18:35
Documents
7
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 6-K q32023form6-k.htm 6-K 22502
2 EX-99.1 2023 THIRD QUARTER INTERIM FINANCIAL STATEMENTS ex991-interimfsseptember30.htm EX-99.1 423326
3 EX-99.2 2023 THIRD QUARTER MD&A ex992-q32023mda.htm EX-99.2 254014
4 EX-99.3 Q3 2023 CERTIFICATION CEO ex993-q32023certificationx.htm EX-99.3 14394
5 EX-99.4 Q3 2023 CERTIFICATION CFO ex994-q32023certificationx.htm EX-99.4 14291
6 oncolyticslogotaglineblueaa.jpg GRAPHIC 355294
7 q32023pipeline9.jpg GRAPHIC 84562
  Complete submission text file 0001129928-23-000067.txt   1285493
Mailing Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5
Business Address 804, 322 - 11 AVENUE SW CALGARY A0 T2R 0C5 4036707380
ONCOLYTICS BIOTECH INC (Filer) CIK: 0001129928 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-38512 | Film No.: 231374976
SIC: 2834 Pharmaceutical Preparations